Lymphovascular invasion represents a superior prognostic and predictive pathological factor of the duration of adjuvant chemotherapy for stage III colon cancer patients

淋巴血管侵犯 医学 旁侵犯 内科学 外科肿瘤学 结直肠癌 阶段(地层学) 肿瘤科 比例危险模型 病态的 化疗 辅助化疗 辅助治疗 生存分析 癌症 胃肠病学 转移 乳腺癌 古生物学 生物
作者
Linjie Zhang,Yuxiang Deng,Songran Liu,Weili Zhang,Zhigang Hong,Zhenhai Lu,Zhizhong Pan,Xiaojun Wu,Jianhong Peng
出处
期刊:BMC Cancer [BioMed Central]
卷期号:23 (1) 被引量:6
标识
DOI:10.1186/s12885-022-10416-7
摘要

Abstract Background Lymphovascular invasion (LVI) and perineural invasion (PNI) can indicate poor survival outcomes in colorectal cancer, but few studies have focused on stage III colon cancer. The current study aimed to confirm the prognostic value of LVI and PNI and identify patients who could benefit from a complete duration of adjuvant chemotherapy based on the two pathological factors. Methods We enrolled 402 consecutive patients with stage III colon cancer who received colon tumor resection from November 2007 to June 2016 at Sun Yat-sen University Cancer Center. Survival analyses were performed by using Kaplan–Meier method with log-rank tests. Risk factors related to disease-free survival (DFS) and overall survival (OS) were identified through Cox proportional hazards analysis. Results 141 (35.1%) patients presented with LVI, and 108 (26.9%) patients with PNI. The LVI-positive group was associated with poorer 3-year DFS (86.5% vs. 76.3%, P = 0.001) and OS (96.0% vs. 89.1%, P = 0.003) rates compared with the LVI-negative group. The PNI-positive group showed a worse outcome compared with the PNI-negative group in 3-year DFS rate (72.5% vs. 86.7%, P < 0.001). Moreover, LVI-positive group present better 3-year DFS and OS rate in patients completing 6–8 cycles of adjuvant chemotherapy than those less than 6 cycles (3-year DFS: 80.0% vs. 64.9%, P = 0.019; 3-year OS: 93.2% vs. 76.3%, P = 0.002). Conclusions LVI is a superior prognostic factor to PNI in stage III colon cancer patients undergoing curative treatment. PNI status can noly predict the 3-year DFS wihout affecting the 3-year OS. Furthermore, LVI also represents an effective indicator for adjuvant chemotherapy duration.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
啦啦鱼发布了新的文献求助10
刚刚
照九州完成签到,获得积分10
刚刚
小红完成签到,获得积分10
刚刚
滑腻腻的小鱼完成签到,获得积分20
刚刚
李解万岁完成签到,获得积分10
1秒前
zjt1111111发布了新的文献求助10
2秒前
平淡南霜完成签到,获得积分10
2秒前
五一完成签到,获得积分10
2秒前
科研工作者完成签到,获得积分10
3秒前
爱岗敬业牛马人完成签到,获得积分10
3秒前
3秒前
YiWei发布了新的文献求助10
3秒前
molotov发布了新的文献求助10
4秒前
4秒前
4秒前
zzzzzz完成签到,获得积分10
5秒前
归尘完成签到,获得积分10
5秒前
打打应助小红采纳,获得10
5秒前
5秒前
共渡完成签到,获得积分10
5秒前
修杰应助科研通管家采纳,获得10
6秒前
修杰应助科研通管家采纳,获得10
6秒前
修杰应助科研通管家采纳,获得10
6秒前
完美世界应助科研通管家采纳,获得10
6秒前
我是老大应助科研通管家采纳,获得10
6秒前
kkkklo完成签到,获得积分10
6秒前
Hello应助科研通管家采纳,获得30
6秒前
6秒前
6秒前
Jasper应助科研通管家采纳,获得10
6秒前
桐桐应助科研通管家采纳,获得10
6秒前
6秒前
DijiaXu应助科研通管家采纳,获得10
7秒前
酷波er应助科研通管家采纳,获得10
7秒前
Lucas应助科研通管家采纳,获得10
7秒前
7秒前
7秒前
7秒前
小二郎应助科研通管家采纳,获得10
7秒前
7秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
A new approach to the extrapolation of accelerated life test data 1000
徐淮辽南地区新元古代叠层石及生物地层 500
Coking simulation aids on-stream time 450
北师大毕业论文 基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 390
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
Robot-supported joining of reinforcement textiles with one-sided sewing heads 360
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4016068
求助须知:如何正确求助?哪些是违规求助? 3556043
关于积分的说明 11319836
捐赠科研通 3289063
什么是DOI,文献DOI怎么找? 1812373
邀请新用户注册赠送积分活动 887923
科研通“疑难数据库(出版商)”最低求助积分说明 812044